ProCE Banner Activity

A New Treatment Option for People With Schizophrenia

Clinical Thought

A novel mechanism of action focused on muscarinic receptors represents a groundbreaking development in the schizophrenia treatment landscape, offering an entirely new approach to managing this debilitating disease. This commentary describes in detail a new combination utilizing a muscarinic receptor agonist and a peripheral muscarinic antagonist. This combination reduces dopamine release without blocking dopamine receptors, thereby avoiding common side effects of traditional antipsychotics. This novel approach signifies a major shift from the dopamine receptor blockade strategy used for the past 70 years.

Released: March 27, 2025

Expiration: March 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH: consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Bristol Myers Squibb, Boehringer Ingelheim, Cadent, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, MedAvante-ProPhase, Merck, Mitsubishi Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, Vanda; speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Bristol Myers Squibb, Eisai, Idorsia, Intra-Cellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, Vanda; individual publicly traded stock/stock options: Bristol Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva.